Attovia Therapeutics (ATTO) Stock Price, News & Analysis

Company Overview

Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on advancing its immunology and inflammation pipeline.

Key Stats

• Today's Range: $22.28 to $25.30
• 50-Day Range: N/A
• 52-Week Range: $16.15 to $28.00
• Volume: 286,053 shs
• Average Volume: 198,680 shs
• Market Capitalization: $1.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.20
• Consensus Rating: Moderate Buy

Attovia Therapeutics Stock Analysis - MarketRank™

Attovia Therapeutics scored higher than 86% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Attovia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Attovia Therapeutics has a consensus price target of $42.20, representing about 72.1% upside from its current price of $24.52.

Amount of Analyst Coverage

Attovia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Attovia Therapeutics are expected to grow in the coming year, from ($4.06) to ($2.38) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of Attovia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Attovia Therapeutics has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Attovia Therapeutics has recently increased by 26.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Attovia Therapeutics does not currently pay a dividend.

Dividend Growth

Attovia Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.17

News Sentiment

Attovia Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Attovia Therapeutics this week, compared to 6 articles on an average week.

MarketBeat Follows

3 people have added Attovia Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

5 insiders have purchased shares of Attovia Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $42,766,833.00 in company stock, which represents 3.8206% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Attovia Therapeutics insiders have bought 949.71% more of their company's stock than they have sold. Specifically, they have bought $47,269,979.00 in company stock and sold $4,503,146.00 in company stock.

Percentage Held by Institutions

Attovia Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/02/2026
• Today: 9/14/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ATTO
• CIK: 2058707
• Web: www.attovia.com
• Phone: (510) 399-5001
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Attovia Therapeutics: $42.20
• High Price Target: $52.00
• Low Price Target: $30.00
• Potential Upside/Downside: +72.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.80 million
• Price / Sales: 621.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 45,651,000
• Free Float: N/A
• Market Cap: $1.12 billion
• Optionable: N/A
• Beta: N/A